What does Sanofi do?

Gain an overview of our core business areas, in which we discover and develop medicines and vaccines for millions of people.

Cardiovascular disease

Building on our decades of fighting cardiovascular disease, we are committed to delivering therapeutic solutions for cardiovascular conditions.


For close to a century we have been developing insulin treatments for diabetes. Building on this heritage, we combine our quality drugs with services to support patients and healthcare systems.

Health and well-being

Self-care supports not only better health, but enables sustainable healthcare systems. It will become increasingly important in years to come. In the UK, Sanofi consumer healthcare has a 50-year heritage, which covers, for example, allergy, pain care, and digestive health.


Our immunology portfolio includes treatments for atopic dermatitis, severe asthma, and rheumatoid arthritis. We are leading the science behind type 2 inflammation, providing treatment options and a robust pipeline of potential new medicines for chronic immune disorders.

Multiple sclerosis

For over ten years we have developed novel treatments for multiple sclerosis (MS). With a portfolio of products, we are committed to maintaining long-term partnerships with our stakeholders to continue to make a significant impact on people living with MS.


Building on a rich legacy in oncology, we are committed to bringing novel treatment options to patients. Today, we have a portfolio of medicines across a variety of cancers, including skin, prostate, lung, colon, breast and blood.

Rare diseases and rare blood disorders

Through in-house development and strategic acquisitions and partnerships, our capabilities within rare diseases focus on genetic lysosomal storage disorders. We also focus on rare blood disorder. Our R&D is working to develop and launch several prospective innovative therapies in this area.


For over 100 years, we have produced vaccines to protect people from infectious diseases while they are at home in the UK and when travelling. We also partner with the public health, medical and scientific communities to improve access to vaccines and increase vaccination coverage.

Find information about our products

MAT-XU-2400405 (v1.0)
March 2024